Edition:
India

Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

4.50USD
19 Jun 2019
Change (% chg)

-- (--)
Prev Close
$4.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,042
52-wk High
$8.61
52-wk Low
$3.66

Latest Key Developments (Source: Significant Developments)

Alpine Immune Sciences Reports Q1 2019 Results, Provides Corporate Update
Thursday, 9 May 2019 

May 9 (Reuters) - Alpine Immune Sciences Inc ::QTRLY CASH & CASH EQUIVALENTS OF $41.4 MILLION VERSUS $10.7 MILLION AS OF PRIOR QUARTER .ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.QTRLY NET LOSS PER SHARE $0.70.EXPECTS TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2021.Q1 EARNINGS PER SHARE VIEW $-0.69 -- REFINITIV IBES DATA.  Full Article

Alpine Immune Sciences Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.QTRLY NET LOSS PER SHARE $0.70.EXPECTS TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2021.Q1 EARNINGS PER SHARE VIEW $-0.69 -- REFINITIV IBES DATA.QTRLY CASH AND CASH EQUIVALENTS $41,437 VERSUS $10,711.  Full Article

Alpine Immune Sciences Expects To Have Sufficient Cash To Fund Operations Into 2021
Monday, 18 Mar 2019 

March 18 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2018 FINANCIAL RESULTS.ALPINE IMMUNE SCIENCES INC - AS OF DECEMBER 31, 2018, HAD CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TOTALING $52.3 MILLION.ALPINE IMMUNE SCIENCES - EXPECT TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2021.  Full Article

Alpine Immune Sciences Reports Q3 Diluted Net Loss Per Share Attributable To Common Stockholders Of $0.88
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.ALPINE IMMUNE SCIENCES INC QTRLY DILUTED NET LOSS PER SHAREATTRIBUTABLE TO COMMON STOCKHOLDERS $0.88.ALPINE IMMUNE SCIENCES INC - EXPECT TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020.  Full Article

Alpine Immune Sciences Qtrly Loss Per Share $0.38
Tuesday, 15 May 2018 

May 14 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $300,000 VERSUS $700,000.ALPINE IMMUNE SCIENCES - REMAIN ON TRACK TO FILE INDS FOR ALPN-101, FOR TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES IN Q4 OF THIS YEAR.QTRLY LOSS PER SHARE $0.38.  Full Article

Alpine Immune Sciences qtrly earnings per share ‍$0.18​
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Alpine Immune Sciences Inc ::Alpine Immune Sciences reports corporate update and third quarter 2017 financial results.Q3 revenue $100,000 versus $700,000.Alpine Immune Sciences Inc - ‍company expects to have cash to fund operations into 2020​.Alpine Immune Sciences Inc qtrly earnings per share ‍$0.18​.  Full Article

Frazier Life Sciences reports 15.8 pct stake in Alpine Immune Sciences
Monday, 31 Jul 2017 

July 31 (Reuters) - Alpine Immune Sciences Inc :Frazier Life Sciences reports 15.8 percent stake in Alpine Immune Sciences as of July 24, 2017 - SEC filing.  Full Article

Alpine Immune Sciences completes merger with Nivalis Therapeutics
Tuesday, 25 Jul 2017 

July 25 (Reuters) - Alpine Immune Sciences:Alpine Immune Sciences Inc completes merger with Nivalis Therapeutics Inc.Nivalis Therapeutics Inc - ‍upon completion of merger and financing, Alpine will have approximately $90 million in cash and cash equivalents​.Nivalis Therapeutics Inc - ‍combined company changed its name to Alpine Immune Sciences​.  Full Article

Nivalis Therapeutics stockholders approve reverse stock split
Thursday, 20 Jul 2017 

July 20 (Reuters) - Nivalis Therapeutics Inc :Nivalis Therapeutics - stockholders approved on July 19 reverse stock split of co's common stock, at ratio of 1 new share for every 4 shares outstanding.Nivalis Therapeutics Inc - stockholders approved all of merger-related proposals in special meeting on July 19.  Full Article